Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GB222 in Relapsed/Progressive High-grade Glioma
NCT04178057Phase 1Unknown
- Sponsor
- Genor Biopharma
- Start
- Oct 2018
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GB222 in glioma (4 arms), sponsored by Genor Biopharma. Primary endpoints: Dose-limiting toxicity at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Status: unknown.
02
Drugs
GB222
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04178057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178057.